

Disclosures

| Persona | l Commercia | 1 (9) |
|-----------------------|-------------|-------|
| ı C ı sona | | |

| Company Name | Relationship Category | Compensation Level | Topic Area(s) |
|---|----------------------------|--------------------------|------------------------------------|
| Self | | | |
| Akcea | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| Amgen Inc. | Other - Fellowship support | Significant (>= \$5,000) | Prevention |
| AstraZeneca Pharmaceuticals | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| BMS-Pfizer | Research/Research Grants | Modest (< \$5,000) | |
| Boeringer-Ingelheim | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| Johnson & Johnson | Research/Research Grants | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| Novo Nordisk Inc. | Consultant Fees/Honoraria | Significant (>= \$5,000) | Prevention |
| Roche Diagnostics | Research/Research Grants | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| Takeda Pharmaceuticals North America, Inc | Research/Research Grants | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |

Additional Personal Commercial Disclosures for Education Activities (1)

| Company Name | Relationship Category | Compensation Level | Topic Area(s) |
|--------------|------------------------------|--------------------|------------------------------------|
| Self | | | |
| CHFS | Other - Organizing committee | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |

Personal Organizational or Other Non-Commercial (6)

| Non-Commercial Enity Name | Relationship Category | Compensation Level | Topic Area(s) |
|---|--|--------------------------|--|
| Self | | | |
| Alberta Innovates Health Solution Clincian Scientist Fellowship † Alberta Innovates Health Solution | Research/Research Grants | Significant (>= \$5,000) | General Cardiology Heart Failure and Cardiomyopathies |
| AREA19 | Other - Board of advisors | None (\$0) | Other |
| Canadian Cardiovascular Society Bayer Vascular Award † Canadian Cardiovascular Society | Research/Research Grants | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| European Society of Cardiology † European Society of Cardiology Young Investigator fellowship | Research/Research Grants | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| FrontRX | Ownership Interest/Partnership/Principal | Modest (< \$5,000) | Other |
| Heart Failure Society of America Young Investigator grant † Heart Failure Society of America | Research/Research Grants | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |

Clinical Trial Enroller (3)

| Trial Name | Trial Sponsor | Trial Funding Source |
|------------|---|----------------------|
| HEART-FID | American Regent | |
| DAPA-AHF | AstraZeneca Pharmaceuticals | |
| EMPACT-MI | Boehringer Ingelheim Pharmaceuticals, Inc | |

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

Agreement

Certified Education Attestation | Signed on 10/11/2023

URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 10/11/2023

URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

Embargo | Signed on 10/11/2023

URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 10/11/2023

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.